Hot Life Science Investor Mandate 1: New $100 Million Fund Invests In Regenerative Medicine Globally

17 Sep

An investment and advisory firm with representatives in California, Boston, and London is managing a $100 million fund focused on regenerative medicine. The firm is looking to build a portfolio of 10-12 early stage regenerative medicine companies, investing up to $10 million per deal with an initial investment of $1-3 million. The firm prefers to lead investments, though is willing to co-invest. A government agency will provide due diligence and commercialization support to the fund’s portfolio companies. The firm invests globally in regenerative medicine.

The fund focuses exclusively on regenerative medicine, including stem cells, cell therapies, immunotherapies, and tissue engineering. The firm is interested in therapeutics, and is actively looking at several immunotherapies, such as those involving T-cells, dendritic cells, and/or checkpoint inhibitors. The firm is open to any indication in the therapeutic space, as long as the underlying regenerative medicine technology is robust, and has demonstrated efficacy that is not incremental, but rather a dramatic change in the way the disease is currently treated. The firm invests in early projects, primarily from the pre-clinical stage through Phase II.

The firm is looking for compelling regenerative medicine technologies, and is prepared to build or augment the management team and/or board of a company, if necessary.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: